	US 12,397,029 B2
	Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors
Liang Deng, New York, NY (US); Jedd Wolchok, New York, NY (US); Taha Merghoub, New York, NY (US); Stewart Shuman, New York, NY (US); Peihong Dai, New York, NY (US); and Weiyi Wang, New York, NY (US)
Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
Filed by Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed on Jan. 13, 2022, as Appl. No. 17/575,462.
Application 17/575,462 is a continuation of application No. 16/741,634, filed on Jan. 13, 2020, granted, now 11,253,560.
Application 16/741,634 is a continuation of application No. 15/565,609, granted, now 10,548,930, issued on Feb. 4, 2020, previously published as PCT/US2016/028184, filed on Apr. 18, 2016.
Claims priority of provisional application 62/149,484, filed on Apr. 17, 2015.
Prior Publication US 2022/0211785 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/768 (2015.01); A61K 39/12 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC A61K 35/768 (2013.01) [A61K 39/12 (2013.01); A61K 39/3955 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); A61K 2039/525 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/57 (2013.01); C12N 2710/24122 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24134 (2013.01); C12N 2710/24171 (2013.01)]

13 Claims

1. A method of eliciting an immune response in a subject with a solid malignant tumor, the method comprising delivering to the tumor cells a therapeutically effective amount of a modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L).